Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Fig. 1

Patient Selection.

*Patients with malignancy who receivied CPIs.

**Eligibility criteria: (1) received IFX and/or CS (dexamethasone, methylprednisolone, and prednisone) and (2) indication for IFX and/or CS definitively for irEC.

***Inadequate documentation of timing of primary endpoints (symptoms resolution).

****Did not meet primary endpoint of symptom resolution or died before resolution of colitis (3 in CS group, 1 in IFX group)

Back to article page